Stocks and Investing
Stocks and Investing
Mon, October 24, 2016
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Andrew Fein Downgraded (VRTX) to Hold on, Oct 24th, 2016
Andrew Fein of HC Wainwright & Co., Downgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Hold on, Oct 24th, 2016.
Andrew has made no other calls on VRTX in the last 4 months.
There are 3 other peers that have a rating on VRTX. Out of the 3 peers that are also analyzing VRTX, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Christopher Raymond of "Raymond James" Initiated at Hold on, Tuesday, September 13th, 2016
These are the ratings of the 2 analyists that currently disagree with Andrew
- Biren Amin of "Jefferies" Maintained at Strong Buy with Increased Target to $105 on, Wednesday, October 5th, 2016
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $139 on, Thursday, July 28th, 2016
Contributing Sources